bullish
SymBio Pharmaceuticals - Treakisym has positive DLBCL results
SUMMARY
On 5 November 2019, SymBio announced it obtained positive results in its pivotal Phase III clinical trial of Treakisym (bendamustine) in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL). The study met its primary endpoint of improvement in response rates, although the company did not give detailed data in its announcement. SymBio guided toward submission of the data to the PMDA in H120 and we expect initial sales in 2021, driving sustained profitability.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Edison Investment Research
Leading International Investment Research
Price Chart(Sign Up to Access)
- SymBio Pharmaceuticals - Treakisym has positive DLBCL results05 Dec 2019
x